Recent News Releases

CSL Appoints New Directors
12 Dec 2017 Company

Dr Brian McNamee AO and Mr Abbas Hussain have been appointed as independent Non-Executive Directors, effective 14 February 2018.

New National Fractionation Agreement
11 Dec 2017 Innovation

CSL Behring today announced that it has signed an agreement with the National Blood Authority, representing all Australian governments, to continue to provide the community with a world-class and secure supply of plasma-derived therapies manufactured in Australia.

Expansion of CSL Biotech Facility
07 Dec 2017 Company

CSL today officially opened a new AUD$230 million advanced manufacturing facility at its CSL Behring site in Broadmeadows with the assistance of Victorian Minister for Industry and Employment, Ben Carroll, MP.

CSL and Vitaeris Strategic Partnership
05 Dec 2017 Innovation

Agreement to expedite the development of clazakizumab (an anti-IL6 MAB, formerly ALD518) as a therapeutic option for solid organ transplant rejection.

CSL112 Phase 3 Clinical Trial
05 Dec 2017 Company

The study will be the largest ever undertaken by CSL, and will enroll more than 17,000 patients from approximately 1,000 sites around the world.

Australian Scientists Awarded $2.5m
17 Oct 2017 Company

Two Australian scientists have each been awarded an AUD$1.25 million, five-year, CSL Centenary Fellowship to further research into gentler, more effective cancer diagnostics and, to advance understanding of what really causes our arteries to clog.

Media Contacts

Christina Hickie

CSL Behring Australia
Senior Manager, Communications
Phone: +61 429 609 762

Want to know more about how CSL, and our CSL Behring division are sharing stories of biotech's promise?

Visit Vita
News archive 2016 pdf
News archive 2015 pdf
News archive 2014 pdf
News archive 2013 pdf

Get our latest news in your inbox
First name
Last name


Thank you for subscribing
to the CSL newsletter